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Abstract 
Isolated left ventricular non-compaction (LVNC) is a rare form of primary 
cardiomyopathy. While increasingly diagnosed, data on outcomes are limited. To define 
predictors of adverse outcomes, we performed a retrospective analysis of a 
prospectively defined cohort of consecutive patients (age >14 years) diagnosed with 
LVNC at a single center. Baseline characteristics included presentation with a 
cardiovascular complication (decompensated heart failure, systemic embolic event or 
sustained ventricular arrhythmia). The primary endpoint was survival free from 
cardiovascular death or transplantation. Predictors of survival were evaluated using the 
Kaplan Meier method and a Cox Proportional Hazards analysis. A total of 115 patients 
were included, 77% of whom were symptomatic at diagnosis. Compared to 
asymptomatic patients, symptomatic patients were significantly older, had larger left 
ventricular cavities and worse left-ventricular ejection fraction. Forty-nine patients (43%) 
presented with a cardiovascular complication. During a median follow-up of 2.7 years 
(range: 0.1 – 19.4), none of the asymptomatic patients died or underwent transplantation 
compared to 31% (27/88) of the symptomatic patients (p = 0.001). The major 
determinants of cardiovascular death or transplantation were presentation with a 
cardiovascular complication (HR 20.6, 95% CI 4.9-87.5, p<0.0001) or NYHA class ≥3 
(HR 8.8, 95% CI 3.2-24.0, p<0.0001). Left ventricular dilatation and systolic dysfunction 
were less strong predictors. In conclusion, in patients with LVNC, NYHA class  3 and 
cardiovascular complications at presentation are strong predictors for adverse outcome. 
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 Isolated left ventricular non-compaction (LVNC) is a rare cardiomyopathy with 
considerable genetic heterogeneity.1,2 Despite its increasing recognition and diagnosis, 
the clinical outcome of this rare entity is not well defined.3-10 11-13 
The aim of this study was to examine clinical outcome in a relatively large, 
prospectively defined cohort of patients with LVNC and to identify risk factors for adverse 
cardiovascular events. 
 
 
Methods 
Diagnostic criteria as previously described by our group were used.14 In the 
absence of other congenital or acquired structural heart disease or neuromuscular 
disorders, these criteria include the presence of a typical two-layered structure of a 
significantly thickened myocardium.  The thickened two-layered myocardium consisted 
of a thin, compacted outer (epicardial) layer and a much thicker, non-compacted inner 
(endocardial) layer with deep intertrabecular recesses filled with blood from the left 
ventricular cavity. A ratio of the non-compacted to compacted layer of > 2, obtained in 
the parasternal short axis view, had to be present at end-systole. All diagnoses were 
established by echocardiography and required independent agreement by two 
experienced echocardiographers (RJ and EO). These criteria were previously validated 
against dilated cardiomyopathy, hypertensive heart disease and valvar heart disease 
and showed good sensitivity and specificity.15 To define the extent of involvement, the 
left ventricle was divided into 9 segments as previously described.5 Left ventricular 
dimensions and function at the time of diagnosis and in follow-up were assessed 
according to established guidelines for two-dimensional echocardiography.16 Left 
ventricular dimensions were normalized for body surface area. 
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Left ventricular non-compaction was diagnosed in 152 consecutive patients over 
the age of 14 years at a single tertiary referral centre, University Hospital, Zurich (0.15% 
of all echocardiograms) between 1984 and 2006. Twenty patients were excluded for 
associated congenital heart disease. This left 132 patients with LVNC in the study 
cohort. The lower age limit of 14 years was chosen to allow enrollment of adolescents 
identified by family screening, but to avoid enrollment of neonatal LVNC or LVNC with 
onset of symptoms in early childhood, a disease entity which is often accompanied by 
syndromic association and may have a different outcome than LVNC diagnosed in 
adulthood.4,6,8  
Clinical characteristics collected at initial presentation were the presence and 
nature of cardiac symptoms, functional class (New York Heart Association classification) 
and the occurrence of cardiovascular complications at the time of initial assessment or 
prior to presentation. The latter comprised decompensated heart failure requiring 
hospital admission, systemic embolic events, sustained ventricular arrhythmias and/or 
presentation with survived sudden cardiac death.  
Figure 1 depicts the number of newly diagnosed patients with LVNC at our 
centre during the study period. The increased number of asymptomatic patients after the 
year 2000 reflects our policy of routine family screening. 
Of the 132 patients within the study cohort 115 (87%) had at least one year of 
follow-up or died or underwent heart transplantation within the first 12 months after 
diagnosis. These 115 patients were included in the survival analysis. Follow-up 
information was collected by retrospective chart review.  Initial presentation and outcome 
of the first 34 patients of the cohort has been reported previously.5 
The primary endpoint included cardiovascular death or heart transplantation. 
Other major adverse events were recorded and included systemic embolism, sustained 
ventricular arrhythmias and admission for heart failure. Cardiovascular death was 
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defined as death directly related to progressive heart failure, sudden death (death within 
one hour of onset of symptoms or acute deterioration of a symptomatic patient with 
previously stable symptoms), death related to cardio-embolic stroke, death caused by 
pulmonary embolism or death ensuing in the immediate sequence of a cardiovascular 
intervention or operation.  
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., 
Chicago, IL). Descriptive data is presented as medians (range), means ( standard 
deviations) and proportions as appropriate. Comparison between survivors and non-
survivors and the groups of patients presenting with and without symptoms was 
performed using Student’s t-test, Mann Whitney or Chi square tests.  Kaplan Meier 
curves were used to depict difference between patients with and without: a) symptoms at 
presentation, b) cardiovascular complications at presentation, c) NYHA class 3, d) left 
ventricular enddiastolic diameter indexed to body surface area > 3.7 cm/m2 and left 
ventricular ejection fraction (LVEF) <35%. Predictors of survival free from cardiovascular 
death or heart transplantation were determined using a Cox proportional hazards model. 
A p-value <0.05 (two-sided) was considered to be significant. 
 
 
Results 
Clinical, echocardiographic and electrocardiographic baseline characteristics of 
the entire study cohort, survivors and patients with cardiovascular death/transplantation 
are summarized in Table 1. At the time of diagnosis, 66 symptomatic patients (50%) 
were on medical treatment. Most common medications were angiotensin converting 
enzyme inhibitors or angiotensin receptor antagonists (36%), beta blockers (38%) and 
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diuretics (26%). Forty-eight patients (36%) were on oral anticoagulation and 9 (7%) on 
low dose Aspirin. 
 Ninety-five patients (72%) were symptomatic at the time of diagnosis. The most 
common symptoms reported by the patients were dyspnea (80%), syncope (16%) and 
palpitations (22%). A large proportion of symptomatic patients presented with a 
cardiovascular complication, including 3 survivors of a sudden cardiac death (Table 1). 
Three patients had a history of transient ischemic attack or stroke (1 month, 2 years and 
10 years prior to the diagnosis of LVNC). All were known to have a cardiomyopathy at 
the time of the embolic event. Some patients presenting with symptoms had been 
previously labeled as ‘dilated cardiomyopathy’ (n = 23, 24%). In those cases the correct 
diagnosis of LVNC was delayed by 5.2 years (range: 0.2-17.3). Five patients (ages 40, 
57, 64, 70 and 72 years) were found to have additional coronary artery disease during 
initial assessment. 
The most common reason for assessment of asymptomatic patients (n = 37) was 
family screening (49%); a total of 30 patients (23%) in our cohort had one or more family 
members affected by LVNC. Other reasons for assessment of asymptomatic patients 
were non-cardiac chest pain, heart murmurs or ECG-abnormalities. Baseline 
characteristics of patients presenting with and without symptoms are compared in Table 
2. At the time of diagnosis 5 asymptomatic patients (14%) had an LVEF below 45% and 
one patient (3%) below 35%. 
Serial follow-up data was available for 27 (73%) asymptomatic and for 88 (93%) 
symptomatic patients. The median follow-up time until last clinic visit or cardiovascular 
death/heart transplantation was 2.7 (range: 0.1 – 19.4) years and was not significantly 
different between survivors and non-survivors [2.7 years (range 1.0-15.8) versus 1.9 
years (range 0.1-19.4), p = 0.14].  Table 3 presents the adverse cardiovascular events in 
the 115 patients at risk. None of the asymptomatic patients experienced any adverse 
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cardiovascular events during follow-up, irrespective of whether they had been diagnosed 
incidentally or by family screening. One asymptomatic patient (4%) had progressive left 
ventricular dilatation with increase of left ventricular enddiastolic diameter from 5.2 cm at 
presentation to 7.2 cm with corresponding decrease in LVEF from 50% to 35% (follow-
up period of 7.9 years). This patient underwent implantation of an implantable 
cardioverter defibrillator (AICD) for primary prevention of sudden cardiac death after 
induction of polymorphic ventricular tachycardia on electrophysiological testing (one year 
after diagnosis). At the time of his last clinical follow up, he remained asymptomatic, 
continued to have a good exercise tolerance and had not experienced any AICD 
discharges. All other patients without symptoms at diagnosis had stable left ventricular 
dimensions and systolic function during follow up.  
Thirty two patients (28%) experienced a total of 52 adverse cardiovascular 
events. Twenty-one patients (18%) died from cardiovascular cause and 6 (5%) 
underwent orthotopic heart transplantation. Sudden cardiac death (48%) was the most 
common cause of death followed by death due to progressive heart failure (38%). One 
patient (5%) died from pulmonary embolism and two patients (10%) died due to a 
complication after cardiac device implantation. Of patients experiencing cardiovascular 
complications, 2 had concomitant coronary artery disease on initial assessment. One of 
these patients died from progressive heart failure and one from postoperative sepsis 
after AICD implantation. 
Out of five patients (4%) with systemic embolic events during follow-up, one had 
atrial fibrillation at the time of the event and only one was on oral anticoagulation after 
successful electrical cardioversion 7 months earlier. The INR was in the therapeutic 
range at the time of the event. There were no significant differences in age at diagnosis, 
left ventricular dimensions and left ventricular function between patients with and without 
systemic embolic events. 
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 Survival free from cardiovascular death or heart transplantation was 86%, 75% 
and 36% at 1, 5 and 10 years, respectively. Univariate determinants of survival free from 
cardiovascular death or transplantation are given in Table 4; Figure 2 shows the 
Kaplan-Meier survival curves for the probability of survival free from cardiovascular 
death or transplantation according to clinical and echocardiographic characteristics. 
Presentation in NYHA functional class  3 or presentation with a cardiovascular 
complication (defined as sustained ventricular arrhythmia, systemic embolization or 
admission with heart failure) were the strongest predictors of the primary endpoint, while 
echocardiographic (left ventricular dilatation and systolic dysfunction) and 
electrocardiographic parameters were less strong predictors. There was strong 
colinearity between all significant univariate predictors, precluding multivariate analysis. 
 
 
Discussion 
Although awareness of LVNC has substantially increased and several small 
series have been published during the last years, overall clinical event rates and 
predictors for poor outcome remain ill-defined.4-12 In this prospectively defined cohort, we 
were able to define the clinical and echocardiographic characteristics of a relatively large 
population of patients with LVNC and to define distinct predictors of cardiovascular death 
or heart transplantation. Symptomatic patients had a high mortality and were at high risk 
for major adverse cardiovascular events. By univariate analysis, the strongest predictors 
for cardiovascular death or heart transplantation were presentation with a cardiovascular 
complication and functional class 3 or more. Adverse left ventricular remodeling with left 
ventricular dilatation and depressed left ventricular ejection fraction were less predictive.  
In agreement with previous reports patients without symptoms at initial 
presentation had a more favorable short- and mid-term outcome.10-12 None of them 
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developed symptoms or had cardiovascular complications albeit five patients had 
impaired left ventricular systolic function at presentation and one had progressive left 
ventricular dilatation and systolic dysfunction during follow-up. However, follow-up in 
these patients was limited and not long enough to be reassured about their long-term 
prognosis. Some of these individuals will likely develop progressive left ventricular 
dysfunction and are at risk for the development of symptoms and complications later in 
life.  
It is concerning that in this series more than half of symptomatic patients 
presented with a clinical cardiovascular complication, including 9 patients (9%) with 
sustained ventricular arrhythmias and 3 patients (3%) with systemic embolization. By 
extrapolation from other forms of cardiomyopathy we speculate that at least some of 
these serious complications might have been preventable by early diagnosis, timely 
institution of evidence based heart failure medication and appropriate device therapy.17  
 Adverse outcomes including mortality and morbidity of patients with LVNC vary 
significantly among different reports and might have been overestimated in earlier 
studies because of inclusion of primarily symptomatic patients referred to tertiary referral 
centers.4-6,9,12 It is of interest, that event rates were lower in recently published cohorts 
than in the previous reports.9,13 In one, recently published series, no deaths occurred in 
patients with normal left ventricular ejection fraction and all patients who died were older 
than 70 years of age.13 These more favorable outcomes in more recently published 
series are likely explained by the inclusion of asymptomatic patients and are consistent 
with findings from our present cohort. Application of evidence-based heart failure therapy 
may be another contributor to the more favorable outcome in more recent series. 
Interestingly, in one series, outcome of patients with LVNC was found to be comparable 
to outcomes in matched patients with dilated cardiomyopathy; this observation suggests 
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that the resultant LV dysfunction, rather than the phenotype or non-compacted 
myocardium itself, is the primary source of morbidity and mortality 13. 
It would be obvious that sarcomere gene mutations may predict the clinical 
phenotype. However, in a recent study comparing sarcomere-mutation positive and 
mutation-negative LVNC probands, no significant differences in terms of the clinical 
phenotype was found. Thus, research is needed to clarify the relationship between the 
type of mutation, genetic modifiers, and the clinical phenotype. 18  
 Our findings underscore the need for regular follow-up of patients with this rare 
cardiomyopathy, in particular close follow-up of symptomatic patients. Given the high 
incidence of complications at presentation, one of our primary goals must be to identify 
patients at risk before complications occur. Offering family screening to relatives of 
patients with an established diagnosis is therefore important. This may allow early 
identification of asymptomatic patients at risk for complications in the future. Timely 
institution of evidence based heart failure treatment in asymptomatic patients with 
worsening left ventricular systolic function may prevent the occurrence of complications.
 There remain however some unresolved problems. In the absence of definitive 
diagnostic criteria, such as genetic testing, the diagnosis of LVNC is established by 
cardiac imaging, most commonly by echocardiography. There are, however, no 
generally accepted criteria on cardiac imaging for establishing the diagnosis of LVNC. 
The criteria proposed by our group and most frequently used by researchers are based 
on the presence of a thickened, two-layered myocardium with a ratio between non-
compacted and compacted myocardium in affected segments of at least 2:1 measured 
during systole in the parasternal short axis view.14 It has been reported that these criteria 
may be too sensitive, particularly in black patients.19 This leaves us with the dilemma of 
potentially overcalling the diagnosis in otherwise healthy individuals with all its 
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implications and even potential implications on insurability. On the other hand, our 
criteria seem to identify a high risk group of symptomatic patients. 
 Although this is one of the largest populations of patients with LNVC, this study is still 
limited by the relatively small number of patients, by the referral bias, by the limited 
follow-up time and by the absence of universally accepted diagnostic criteria for 
LVNC. We have tried to overcome some of the operator dependent factors, which 
may affect interpretation of images by independent review of the images by two 
experienced echocardiographers (RJ and EO). Differences in interpretation were 
adjudicated by reviewers by joint interpretation. Systematic family screening of all 
affected patients was not available which may underestimate the number of 
asymptomatic individuals. In addition, our study population was recruited from a 
tertiary referral center and may represent a highly selected group. The true 
prevalence of LNVC in the general population and thus the general outcome of 
asymptomatic patients with LVNC are still not known and need to be further 
elucidated. Because of strong colinearity between significant univariate predictors, 
we were unable to perform a multivariate survival analysis. 
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Figure legends 
 
Figure 1: Number of patients newly diagnosed with isolated left ventricular non-
compaction at our centre 1984 and 2006 
 
Figure 2: Probability of survival free from cardiovascular death or transplantation 
(Kaplan Meier curves). 
Panel A: Overall survival. Panel B: Survival stratified for presentation with symptoms; 
Panel C: Survival stratified for presentation with a clinical complication (decompensated 
heart failure, sustained ventricular arrhythmia, systemic embolic event); Panel D: 
Survival stratified for NYHA class  3 at presentation; Panel E: Survival stratified for 
severe left ventricular dilatation at presentation; Panel F: Survival stratified for severe left 
ventricular systolic dysfunction at presentation. 
